RoccoJCrescenzoDO

PubMed

• 12 citations
  Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
  Vamsi Kota, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Jeffrey H. Lipton, Dong-Wook Kim
  Leukemia Research. 2021-08-21
• 12 citations
  Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase...
  Jorge E. Cortes, B. Muresan, Carla Mamolo, Joseph C. Cappelleri, Rocco J. Crescenzo
  Current Medical Research and Opinion. 2019-05-15
• 15 citations
  Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
  Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah
  Journal of Cancer Research and Clinical Oncology. 2019-04-15

Journal Articles

• Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial  
  Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo R..., Gynecol Oncol, 1/1/2015
• An Immunological Analysis of Mesodermal Myogenic and Connective Tissue Precursors of the Chick Embryo  
  Crescenzo RJ, Journal of Cell Biology, 1/1/1990
• Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA31 (lapatinib vs trastuzumab)  
  Crescenzo RJ, Breast Cancer Research

Books/Book Chapters

• Blood Products and Pharmacologic Agents in the Treatment of Congenital and Acquired Bleeding Disorders 
  Chapter: Treatment Choices in Hemophilia A and B 
  Page 309 - 339Konkle BA, Crescenzo REditors: Alving B.American Association of Blood Banks, Bethesda, MD2000

Abstracts/Posters

• Bosutinib vs. imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: results by 3-month BCR-ABL1 transcript level.
  Crescenzo RJ, ESH-iCMLF, 1/1/2017
• Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: results from Neo-ALTTO (BIG ...
  Serena Di Cosimo, Christine Campbell , Hatem A. Azim Jr., Giuseppe Curigliano, Carmen Criscitiello, Rocco J Crescenzo, Martine J. Piccart-Gebhart, Holger Eidtmann, Jos..., SABC, 1/1/2015
• HLA-DRB1*7:01 Biomarker Characterization of Hepatotoxicity During Lapatinib Combination Therapies in ALTTO
  Spraggs C, Parham L, Liling W, Williams L, Briley LP, Fraser DJ, Aziz Z, Tong Z, Moodley S, Mehta AO, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow JR, Cres..., Abstract 617 ASCO, 1/1/2015
• LBA7 - Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) in the adjuvant trea...
  Crescenzo RJ, (ID 5684) ESMO, 1/1/2014
• Lapatinib/taxane versus trastuzumab/taxane therapy as first line treatment in metastatic breast cancer: effects of six centrally confirmed biomarkers in NCIC CTG MA.31
  Crescenzo RJ, ASCO, 1/1/2014
• Comparison of PFS and safety for Asian compared to North American and European populations in the Phase III trial of pazopanib vs. sunitinib in treatment naive RCC pat...
  Crescenzo RJ, J Clin Oncol, ASCO-GU, 1/1/2013
• Quality of life (QoL) Among Patients with Renal Cell Carcinoma (RCC) treated with Pazopanib versus Sunitinib in the COMPARZ study.
  Crescenzo RJ, J Clin Oncol, ASCO-GU, 1/1/2012
• Genome wide pharmacogenetic analysis discovers novel association with a surrogate endpoint for efficacy in pazopanib-treated patients with ovarian cancer.
  Crescenzo RJ, Scinovations internal meeting
• Join now to see all

Lectures

• Infections in post-Bone Marrow Transplant Patients 
  Hershey Lodge and Convention Centre, Hershey, PA, 2004, 2007, 2009, 2012 - 1/1/2012
• Use of TKI in Renal and Ovarian cancer 
  Multiple Locations, 2008, 2009, 2011 - 1/1/2011
• Angiogenesis inhibitors in ovarian cancer 
  Hershey, PA - 1/1/2010
• Personalized care in cancer medicine 
  1/1/2010
• Advances in the Diagnosis & Treatment of Cancer 
  Lancaster, PA, 2007, 2008, 2009, 2010 - 1/1/2010
• Clinical research in primary care 
  Hershey, PA - 1/1/2009
• Screening for breast and prostate cancer 
  1/1/2009
• Oncology Update for Primary Care Physicians 
  St. Luke's Hospital, Allentown, PA - 1/1/2005
• Screening Recommendations for Colon and Breast Cancer 
  St. Luke's Hospital, Allentown, PA - 1/1/2005
• Current Topics in Urology 
  Philadelphia, PA - 1/1/2005
• Update on Advances in Prostate Carcinoma 
  Philadelphia, PA - 1/1/2005
• Multiple Myeloma 
  Roxborough Memorial Hospital, Philadelphia, PA - 1/1/2005
• Porphyrias 
  Medical College of Pennsylvania, Philadelphia, PA - 1/1/2003
• Update on Chronic Myelogenous Leukemia 
  Philadelphia, PA - 1/1/2003
• Iron deficiency anemia versus Thalassemia 
  Philadelphia College of Osteopathic Medicine, Philadelphia, PA - 1/1/2003
• Large Granular Lymphocytic Leukemia 
  Thomas Jefferson University, Philadelphia, PA - 1/1/1998
• Join now to see all

Other

• Biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 blockade with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for ... 
  Crescenzo RJ, Clinical Cancer Research (Manuscript # CCR-14-2611)